This investigation has shown that FMT and anti-PD-1 altered the intestinal microbiome and reprogrammed the tumor microenvironment to surmount resistance to anti-PD-1 in a subgroup of PD-1 advanced melanoma [233]. The gene discussed is PDCD1; the disease is neoplasm.